The efficacy and safety of systemic corticosteroids as first line treatment for granulomatous lymphocytic interstitial lung disease

MLA

Immuno/reuma onderzoek 1 (Vastert), et al. The Efficacy and Safety of Systemic Corticosteroids as First Line Treatment for Granulomatous Lymphocytic Interstitial Lung Disease. 2023. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1432122450&authtype=sso&custid=ns315887.

APA

Immuno/reuma onderzoek 1 (Vastert), Cluster B, Immuno/reuma patientenzorg, Child Health, Infection & Immunity, Smits, B., Goldacker, S., Seneviratne, S., Malphettes, M., Longhurst, H., Mohamed, O. E., Witt-Rautenberg, C., Leeman, L., Schwaneck, E., Raymond, I., Meghit, K., Uhlmann, A., Winterhalter, C., van Montfrans, J., … Warnatz, K. (2023). The efficacy and safety of systemic corticosteroids as first line treatment for granulomatous lymphocytic interstitial lung disease.

Chicago

Immuno/reuma onderzoek 1 (Vastert), Cluster B, Immuno/reuma patientenzorg, Child Health, Infection & Immunity, Bas Smits, Sigune Goldacker, et al. 2023. “The Efficacy and Safety of Systemic Corticosteroids as First Line Treatment for Granulomatous Lymphocytic Interstitial Lung Disease.” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1432122450&authtype=sso&custid=ns315887.